56 results on '"Talpaz, Moshe"'
Search Results
2. Ruxolitinib for the treatment of patients with polycythemia vera
3. Ponatinib in Philadelphia Chromosome–Positive Leukemias
4. Ponatinib in patients with refractory acute myeloid leukaemia: findings from a phase 1 study
5. The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo-controlled, Phase III study in patients with myelofibrosis
6. Ponatinib in Refractory Philadelphia Chromosome–Positive Leukemias
7. A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis
8. Protein cross-linking as a novel mechanism of action of a ubiquitin-activating enzyme inhibitor with anti-tumor activity
9. Targets and effectors of the cellular response to aurora kinase inhibitor MK-0457 (VX-680) in imatinib sensitive and resistant chronic myelogenous leukemia
10. Following the Hedgehog to New Cancer Therapies
11. Dasatinib Resistance in Patients with Chronic Myelogenous Leukemia: Identification of a Novel bcr-abl Kinase Domain Mutation
12. Association Between Imatinib-Resistant BCR-ABL Mutation-Negative Leukemia and Persistent Activation of LYN Kinase
13. Efficacy of Various Doses and Schedules of Second-Generation Tyrosine Kinase Inhibitors
14. Outcome of Patients With Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia Post-Imatinib Mesylate Failure
15. New Insights into the Pathophysiology of Chronic Myeloid Leukemia and Imatinib Resistance
16. Dasatinib in Chronic Myelogenous Leukemia
17. Dasatinib in Imatinib-Resistant Philadelphia Chromosome-Positive Leukemias
18. Staging of chronic myeloid leukemia in the imatinib era: An Evaluation of the World Health Organization Proposal
19. Pregnancy Among Patients With Chronic Myeloid Leukemia Treated With Imatinib
20. Pilot study of lonafarnib, a farnesyl transferase inhibitor, in patients with chronic myeloid leukemia in the chronic or accelerated phase that is resistant or refractory to imatinib therapy
21. Significance of myelofibrosis in early chronic-phase, chronic myelogenous leukemia on imatinib mesylate therapy
22. Interferon α therapy for patients with essential thrombocythemia: Final results of a phase II study initiated in 1986
23. Phase II Study of Low-Dose Decitabine in Patients With Chronic Myelogenous Leukemia Resistant to Imatinib Mesylate
24. Survival benefit with imatinib mesylate therapy in patients with accelerated-phase chronic myelogenous leukemia—Comparison with historic experience
25. Chronic Myeloid Leukemia: Current Application of Cytogenetics and Molecular Testing for Diagnosis and Treatment
26. Results of imatinib mesylate therapy in chronic myelogenous leukaemia with variant Philadelphia chromosome
27. Pharmacokinetics and Pharmacodynamics of Imatinib in a Phase I Trial With Chronic Myeloid Leukemia Patients
28. The Role of Imatinib in the Treatment of Chronic Myelogenous Leukemia
29. Philadelphia Chromosome–Positive Leukemias: From Basic Mechanisms to Molecular Therapeutics
30. Bone marrow cyclooxygenase-2 levels are elevated in chronic-phase chronic myeloid leukaemia and are associated with reduced survival
31. STI-571 IN CHRONIC MYELOGENOUS LEUKAEMIA
32. Hematologic and Cytogenetic Responses to Imatinib Mesylate in Chronic Myelogenous Leukemia
33. CELLULAR SIGNALLING PATHWAYS: NEW TARGETS IN LEUKAEMIA THERAPY
34. Pilot Study of Low-Dose Interleukin-11 in Patients With Bone Marrow Failure
35. Chronic Myelogenous Leukemia
36. BCR Rearrangement–Negative Chronic Myelogenous Leukemia Revisited
37. Activity of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in the Blast Crisis of Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia with the Philadelphia Chromosome
38. Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia
39. Homoharringtonine and Low-Dose Cytarabine in the Management of Late Chronic-Phase Chronic Myelogenous Leukemia
40. Cell-penetrating SH3 domain blocker peptides inhibit proliferation of primary blast cells from CML patients
41. STI571: A tyrosine kinase inhibitor for the treatment of CML. (originally presented at ASH 1999. Abstract 1639)
42. Chronic myelogenous leukaemia with p185BCR/ABL expression: characteristics and clinical significance
43. Chronic Myelogenous Leukemia: Biology and Therapy
44. Mechanisms of Disease: The Biology of Chronic Myeloid Leukemia
45. Interleukin-1 increases expression of the LYT-10 (NFκB2) proto-oncogene/transcription factor in renal cell carcinoma lines
46. 1,25-Dihydroxyvitamin D sub 3 and its Analogues Inhibit Acute Myelogenous Leukemia Progenitor Proliferation by Suppressing Interleukin-1beta Production
47. Prognostic Value of Serum Interleukin-6 in Diffuse Large-cell Lymphoma
48. Comparison of bcr-abl Protein Expression and Philadelphia Chromosome Analyses in Chronic Myelogenous Leukemia Patients
49. Cost-Effectiveness of Interferon-alpha and Conventional Chemotherapy in Chronic Myelogenous Leukemia
50. Low-Dose Interferon-alpha in Chronic Myeloid Leukemia
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.